Marketing authorisation applications referred under Article 29

AI Summary

This regulatory guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) details the procedures for Marketing Authorisation Applications (MAAs) involved in Article 29 referrals under Directive 2001/83/EC. Such referrals are triggered when EU member states fail to reach a consensus on an application due to potential serious risks to public health. Although the document does not target a specific company, inspection date, or violation, it clarifies the MHRA's role as the competent authority for Northern Ireland within the EU's mutual-recognition and decentralised procedures. The regulatory framework dictates that decisions reached by the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) or the Committee for Medicinal Products for Human Use (CHMP) are binding for Northern Ireland. This mandate continues through and beyond January 2025. For UK-wide authorisations, the MHRA intends to apply these referral outcomes across the entire UK to ensure regulatory alignment, unless specific domestic changes necessitate withdrawing Northern Ireland from the procedure. Applicants are required to wait for the conclusion of the Article 29 referral process before the MHRA proceeds with final determination of the application. This protocol ensures that any serious public health concerns identified during the evaluation process are fully addressed before a product is permitted on the market in Northern Ireland and, by extension, the broader United Kingdom.